The investigators intend to assess the role of several biomarkers in the prediction of relapse in IBD. Clinical, laboratory and endoscopic data will be gathered and a predictive score will be derived in order to assess the relapse risk at 1 year.
Patients with a confirmed diagnosis of IBD will be prospectively assessed on a yearly basis in order to assess relapse risk factors. Disease activity will be assessed using the Mayo score for UC patients and CDAI for Crohn's disease and endoscopic activity will be assessed using the Mayo endoscopic subscore for UC patients and the Simple Endoscopic Score for Crohn's Disease for CD patients. Serum and fecal biomarkers will be obtainted at each study visit (C-reactive protein, fecal calprotectin). Data about current and past medication for IBD will also be gathered.
Study Type
OBSERVATIONAL
Enrollment
50
Colentina Clinical Hospital
Bucharest, Romania
RECRUITINGClinical relapse
clinical relapse as assessed by conventional scores for activity in IBD - Mayo or CDAI
Time frame: 1 year
Prevalence of NAFLD
to assess the prevalence of nonalcoholic liver disease in IBD patients
Time frame: 1 year
prevalence of vitamin D deficiency
to assess vitamin D deficiency and osteopenia among IBD patients
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.